CENTOGENE Announces Preliminary Full Year 2023 Revenue

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/18/2811370/0/en/CENTOGENE-Announces-Preliminary-Full-Year-2023-Revenue.html

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits.

Read more at globenewswire.com

Related news for (CNTG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.